MKMaria Kontoyianni

Maria Kontoyianni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Kontoyianni has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 5,5′-Methylenedisalicylic Acid Derivatives as Inhibitors of the Protein Phosphatase CppA in Chlamydia trachomatis

    by Krishna Pandey, Olivia Slater, Gabrielle E. Jeschke, Maria Kontoyianni, Kyle N. Plunkett, Derek J. Fisher

    A structure-based designed library of new 5,5'-methylenedisalicylic acid (MDSA) derivatives were synthesized as a functional core and explored for their antibacterial activity against Chlamydia trachomatis. Various well-established reactions such as amide coupling, basic ester hydrolysis, phosphorylation, sulfonation, acetylation, and hydrogenation reactions were utilized to tune or substitute the carboxylic acid and phenolic groups of MDSA, converting them into amide, ester, phosphoryl, sulfonyl, and acetyl functionalities. Both symmetrical and asymmetrical derivatives were prepared and subsequently tested for mammalian cell cytotoxicity, CppA enzyme inhibition, and the inhibition of infection. Among these, compounds 3, 4, and 10a were identified as the most potent and biologically active inhibitors. Additionally, the docking results against the newly constructed CppA model revealed that MDSA and compounds 2-4 form interactions with different residues such as G42, R166, N167, and R237, supporting the requirement of these interactions for biological activity.

  • Open Access

    Factors Driving Amyloid Beta Fibril Recognition by Cell Surface Receptors: A Computational Study

    by Olivia Slater, Maria Kontoyianni

    Alzheimer’s disease (AD) has been studied extensively and is characterized by plaques deposited throughout the brain. Plaques are made of beta-amyloid (Aβ) peptides which have undergone fibrillogenesis to form insoluble Aβ fibrils (fAβ) that are neurotoxic. Receptor for Advanced Glycation End end products (RAGE), toll-like receptors (TLRs) 2 and 4, and co-receptor CD14 recognize negatively charged binding regions on fAβ to activate microglia and release proinflammatory cytokines. In this study, we used two experimentally resolved fAβ structures (type I and II) isolated from AD brain tissue to elucidate binding patterns of fAβ with RAGE, TLR2, TLR4, and CD14 and investigated whether binding was affected by fibril structure or system pH. Receptors TLR2 and RAGE formed tight complexes with both type I and II fibrils, while TLR4 showed selectivity for type I. CD14 binding was less tight and selective for type II. Binding was pH dependent for CD14, TLR4, and RAGE but not TLR2. We explored the effects of familial mutations on fibril structure to determine whether mutants of type I or II structures are feasible. Finally, we investigated whether mutations affected binding interactions of fAβ with proteins. The Arctic (Glu22Gly), Dutch (Glu22Gln), and Iowa (Asp23Asn) mutations showed similar effects on binding affinity. Italian (Glu22Lys) mutations abrogated binding, whereas type I and II fibrils with Flemish (Ala21Gly) mutations were not shown to be feasible. Results highlight the adaptability of immune receptors in recognizing damaging molecules, with fibril structure and pH being the main recognition determinants predicated on disease progression. In silico mutations showed that aggregates similar to type I and II structures were plausible for some familial mutations.


  • Open Access

    5,5'-Methylenedisalicylic acid Derivatives as Inhibitors of the Protein Phosphatase CppA in Chlamydia trachomatis

    by Krishna Pandey, Olivia Slater, Gabrielle Jeschke, Maria Kontoyianni, Kyle Plunkett, Derek Fisher

    A structure-based designed library of new 5,5’-methylenedisalicyclic acid (MDSA) derivatives were synthesized as a func-tional core and explored for their anti-bacterial activity against Chlamydia trachomatis. Various well-established reactions such as amide coupling, basic ester hydrolysis, phosphorylation, sulfonation, acetylation, and hydrogenation reactions were utilized to tune or substitute the carboxylic acid and phenolic groups of MDSA, converting them into amide, ester, phos-phoryl, sulfonyl and acetyl functionalities. Both symmetrical and asymmetrical derivatives were prepared and subsequently tested for mammalian cell cytotoxicity, CppA enzyme inhibition, and inhibition of infection.


  • Open Access

    Elucidating structural and molecular requirements of somatostatin subtype-4 agonist bound complexes using quantum mechanics approaches

    by Olivia Slater, Maria Kontoyianni

    Somatotropin-release Inhibiting Factor (SRIF) binds somatostatin subtype-4 receptor (sst4) within the neocortex to increase amyloid beta catabolism, and possibly effects neuronal plaque formation and disease progression of Alzheimer's disease.

  • Library size in virtual screening: is it truly a number’s game?

    by Maria Kontoyianni

    Drug discovery and development is a long and expensive enterprise. Looking back at the advances made toward various stages of the drug discovery paradigm, a persistent pattern emerges: researchers ...


  • Development of a Simple and Effective Lipid-A Antagonist Based on Computational Prediction

    by Olivia Slater, Kapur B. Dhami, Ganesh Shrestha, Maria Kontoyianni, Michael R. Nichols, Alexei V. Demchenko

    Sepsis is a serious medical condition characterized by bacterial infection and a subsequent massive systemic inflammatory response. In an effort to identify compounds that block lipopolysaccharide (LPS)-induced inflammation reported herein is the development of simple Lipid-A analogues that lack a disaccharide core yet still possess potent antagonistic activity against LPS. The structure of the new lead compound was developed based on predictive computational experiments. LPS antagonism by the lead compound was not straightforward, and a biphasic effect was observed suggesting a possibility of more than one binding site. An IC50 value of 13 nM for the new compound was determined for the possible high affinity site. The combination of computational, synthetic, and biological studies revealed new structural determinants of these simplified analogues. It is expected that the acquired information will aid future design of LPS targeting glycopharmaceuticals.


  • Open Access

    A computational study of somatostatin subtype-4 receptor agonist binding

    by Olivia Slater, Maria Kontoyianni

    The somatostatin subtype-4 receptor (sst4) is highly expressed in neocortical and hippocampal areas, which are affected by amyloid beta accumulation. Sst4 agonists enhance downstream activity of amyloid beta peptide catabolism through neprilysin and may slow the progression of Alzheimer’s disease (AD). Sst4 is a G protein coupled receptor (GPCR), the structure of which has yet to be resolved. A newly constructed sst4 homology model, along with a previously reported model-built sst4 receptor structure, were used in the present study to gain insights into binding requirements of sst4 agonists employing a set of compounds patented by Boehringer Ingelheim. Besides aiming at delineating binding at the macromolecular level of these recently disclosed compounds, our objectives included the generation of a quantitative structure-activity relationship (QSAR) global model to explore the relationship between chemical structure and affinity. Through the implementation of model building, docking, and QSAR, plausible correlations between structural properties and the binding affinity are established. This study sheds light on understanding binding requirements at the sst4 receptor. Graphical abstract


  • Open Access

    RSK1 vs. RSK2 Inhibitory Activity of the Marine β-Carboline Alkaloid Manzamine A: A Biochemical, Cervical Cancer Protein Expression, and Computational Study

    by Alejandro M. S. Mayer, Mary L. Hall, Joseph Lach, Jonathan Clifford, Kevin Chandrasena, Caitlin Canton, Maria Kontoyianni, Yeun-Mun Choo, Dev Karan, Mark T. Hamann

    Manzamines are complex polycyclic marine-derived β-carboline alkaloids with reported anticancer, immunostimulatory, anti-inflammatory, antibacterial, antiviral, antimalarial, neuritogenic, hyperlipidemia, and atherosclerosis suppression bioactivities, putatively associated with inhibition of glycogen synthase kinase-3, cyclin-dependent kinase 5, SIX1, and vacuolar ATPases. We hypothesized that additional, yet undiscovered molecular targets might be associated with Manzamine A’s (MZA) reported pharmacological properties. We report here, for the first time, that MZA selectively inhibited a 90 kDa ribosomal protein kinase S6 (RSK1) when screened against a panel of 30 protein kinases, while in vitro RSK kinase assays demonstrated a 10-fold selectivity in the potency of MZA against RSK1 versus RSK2. The effect of MZA on inhibiting cellular RSK1 and RSK2 protein expression was validated in SiHa and CaSki human cervical carcinoma cell lines. MZA’s differential binding and selectivity toward the two isoforms was also supported by computational docking experiments. Specifically, the RSK1-MZA (N- and C-termini) complexes appear to have stronger interactions and preferable energetics contrary to the RSK2–MZA ones. In addition, our computational strategy suggests that MZA binds to the N-terminal kinase domain of RSK1 rather than the C-terminal domain. RSK is a vertebrate family of cytosolic serine-threonine kinases that act downstream of the ras-ERK1/2 (extracellular-signal-regulated kinase 1/2) pathway, which phosphorylates substrates shown to regulate several cellular processes, including growth, survival, and proliferation. Consequently, our findings have led us to hypothesize that MZA and the currently known manzamine-type alkaloids isolated from several sponge genera may have novel pharmacological properties with unique molecular targets, and MZA provides a new tool for chemical-biology studies involving RSK1.


  • The compromise of virtual screening and its impact on drug discovery

    by Olivia Slater, Maria Kontoyianni

    Introduction: Docking and structure-based virtual screening (VS) have been standard approaches in structure-based design for over two decades. However, our understanding of the limitations, potential, and strength of these techniques has enhanced, raising expectations. Areas covered: Based on a survey of reports in the past five years, we assess whether VS: (1) predicts binding poses in agreement with crystallographic data (when available); (2) is a superior screening tool, as often claimed; (3) is successful in identifying chemical scaffolds that can be starting points for subsequent lead optimization cycles. Data shows that knowledge of the target and its chemotypes in postprocessing lead to viable hits in early drug discovery endeavors. Expert opinion: VS is capable of accurate placements in the pocket for the most part, but does not consistently score screening collections accurately. What matters is capitalization on available resources to get closer to a viable lead or optimizable series. Integration of approaches, subjective hit selection guided by knowledge of the receptor or endogenous ligand, libraries driven by experimental guides, validation studies to identify the best docking/scoring that reproduces experimental findings, constraints regarding receptor–ligand interactions, thoroughly designed methodologies, and predefined cutoff scoring criteria strengthen VS’s position in pharmaceutical research.


  • Toward Computational Understanding of Molecular Recognition in the Human Metabolizing Cytochrome P450s

    by Maria Kontoyianni, Brett Lacy

    Cytochrome P450s are enzymes capable of metabolizing a wide variety of drugs. Their significant impact in drug discovery has led to extensive research, computationally and experimentally, in order to explore how a chemical entity responds to metabolizing enzymes. We present an overview of ligand-based and structure-based methodologies, along with pertinent information on the structures, biology, and relevance of these enzymes.